Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Cancer Res. 2017 Apr 20;77(9):2191–2196. doi: 10.1158/0008-5472.CAN-16-2523

Figure 1. Bispecific Antibody Pretargeted Radioimmunotherapy.

Figure 1

A bispecific antibody construct was engineered that spontaneously dimerizes after expression by CHO-DG44 cells. One single chain antibody fragment binds with high affinity to the CD20 antigen on B cell malignancies, whereas the other single chain antibody fragment binds with exceptionally high affinity to an 90Yttrium-DOTA hapten.